Stockscreener 앱 받기
0.6797
2.93%
-0.0205
전일 마감가:
$0.7002
열려 있는:
$0.714
하루 거래량:
305.04K
Relative Volume:
0.09
시가총액:
$35.19M
수익:
-
순이익/손실:
$-81.22M
주가수익비율:
-0.2296
EPS:
-2.96
순현금흐름:
$-74.41M
1주 성능:
-8.89%
1개월 성능:
-20.80%
6개월 성능:
-12.86%
1년 성능:
-43.83%
1일 변동 폭
$0.67
$0.7299
1주일 범위
$0.67
$0.75
52주 변동 폭
$0.63
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
명칭
Xilio Therapeutics Inc
전화
617-833-1027
주소
828 WINTER STREET, WALTHAM
XLO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.6797 | 35.19M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-21 | 개시 | Chardan Capital Markets | Buy |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
| 2021-11-16 | 개시 | Cowen | Outperform |
| 2021-11-16 | 개시 | Guggenheim | Buy |
| 2021-11-16 | 개시 | Morgan Stanley | Overweight |
| 2021-11-16 | 개시 | Raymond James | Outperform |
모두보기
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Expands Immuno-Oncology Team: 23K Shares Granted to New Biotech Talent - Stock Titan
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 17.1% in March - Defense World
Xilio Therapeutics (XLO) to Release Quarterly Earnings on Monday - Defense World
Head to Head Contrast: Xilio Therapeutics (NASDAQ:XLO) and Janone (NASDAQ:ALTS) - Defense World
Deals In Depth: February 2025 - insights.citeline.com
Xilio Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World
Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating for Xilio Therapeutics - TipRanks
Xilio advances cancer treatments, secures AbbVie collaboration By Investing.com - Investing.com Australia
Xilio Therapeutics May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time - Marketscreener.com
Xilio Therapeutics inks $50M sales agreement with Leerink Partners - Investing.com India
Xilio Therapeutics inks $50M sales agreement with Leerink Partners By Investing.com - Investing.com UK
Form 424B5 Xilio Therapeutics, Inc. - StreetInsider.com
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Xilio advances cancer treatments, secures AbbVie collaboration - Investing.com India
Xilio Therapeutics, Inc. SEC 10-K Report - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results - TradingView
Xilio Therapeutics Provides Pipeline Progress Update and Anticipates Additional Vilastobart Data in Mid-2025 - Nasdaq
Insider Sale Alert: Xilio Therapeutics Inc [XLO] – Is it Time to sell? - Knox Daily
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest - Defense World
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Xilio's Novel Immunotherapy Platform Transform Cancer Treatment? CEO Reveals Latest Progress - StockTitan
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 12.3% – Here’s What Happened - Defense World
Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN
Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle
Abbvie Inc. Reports 9.0 % Passive Stake In Xilio Therapeutics, Inc. As Of Feb 11SEC Filing - Marketscreener.com
Top Biotech Stocks To Keep An Eye OnFebruary 12th - MarketBeat
Stock summary: Xilio Therapeutics ended the week with a surge of 70.12% - Business Upturn
Latham Advises AbbVie on Collaboration and Option Agreement With Xilio Therapeutics and Related Equity Investment - Latham & Watkins LLP
Xilio shares soar on AbbVie collaboration deal - MSN
AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn - PMLiVE
Top Biotech Stocks To Keep An Eye On – February 12th - Defense World
AbbVie Deal Unmasks Promise Of Xilio’s T-Cell Engagers - News & Insights
Xilio advances masked T-cell engagers targeting PSMA, CLDN18.2 and STEAP1 - BioWorld Online
Xilio Therapeutics: Innovative TCE Platform and Strategic AbbVie Partnership Justify Buy Rating - TipRanks
AbbVie and Xilio Therapeutics announce collaboration and option agreement - MSN
We're Hopeful That Xilio Therapeutics (NASDAQ:XLO) Will Use Its Cash Wisely - Simply Wall St
Petri Dish: a new AbbVie deal, layoffs, and CFO departures - The Business Journals
AbbVie partners with Xilio to develop tumour-activated immunotherapies - World Pharmaceutical Frontiers
AbbVie and Xilio to collaborate on antibody-based immunotherapies - Yahoo Finance
AbbVie Stock: $2.1B Cancer Therapy Deal Boosts Portfolio - sharewise
Xilio Gains 125% on New Deal with AbbVie to Target Prostate and Other Cancers - PUNE.NEWS
AbbVie pens another T cell engager deal, this time with Xilio - Endpoints News
AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B - BioSpace
Xilio soars after tie-up with AbbVie to develop cancer treatments - TradingView
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? - Benzinga
Stock market today: Spire Global plunged by 48.97% while Xilio Therapeutics surged by 102.16% in early trading - Business Upturn
AbbVie inks another billion-dollar oncology deal - Crain's Chicago Business
AbbVie, Xilio Hook up - Baystreet.ca
Xilio Therapeutics Inc (XLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):